

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “**EGM**”) of 深圳市海王英特龍生物技術股份有限公司 (Shenzhen Neptunus Interlong Bio-technique Company Limited*) (the “**Company**”, together with its subsidiaries, the “**Group**”) will be held at 10:00 a.m. on Tuesday, 31 December 2024 at Meeting Room, 24th Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Nanshan District, Shenzhen, Guangdong Province, the People's Republic of China (the “**PRC**”), for the purpose of considering and, if thought fit, passing, with or without modifications, the following resolution.

ORDINARY RESOLUTIONS

1. “**THAT**

- (a) the form and substance of the supplemental agreement (the “**2023 Supplemental Yidianyao Distribution Agreement**”) dated 15 November 2024 entered into between the Company and 深圳市海王易點藥醫藥有限公司 (Shenzhen Neptunus Yidianyao Pharmaceutical Company Limited*) (a copy of the 2023 Supplemental Yidianyao Distribution Agreement has been produced to the meeting and marked “A” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;

- (b) the proposed revision of the Existing Annual Cap to the Revised Annual Cap under the 2023 Supplemental Yidianyao Distribution Agreement for the year ending 31 December 2024 be and is hereby confirmed and approved; and
- (c) any one director of the Company (the “**Director**”) be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2023 Supplemental Yidianyao Distribution Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the 2023 Supplemental Yidianyao Distribution Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”

2. “**THAT**

- (a) the form and substance of the distribution agreement (the “**2024 Yidianyao Distribution Agreement**”) dated 15 November 2024 entered into between the Company and 深圳市海王易點藥醫藥有限公司 (Shenzhen Neptunus Yidianyao Pharmaceutical Company Limited*) (a copy of the 2024 Yidianyao Distribution Agreement has been produced to the meeting and marked “B” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;
- (b) the proposed sales caps under the 2024 Yidianyao Distribution Agreement for each of the three years ending 31 December 2025, 2026 and 2027 be and is hereby confirmed and approved; and
- (c) any one Director be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2024 Yidianyao Distribution Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the 2024 Yidianyao Distribution Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”

3. “**THAT**

- (a) the form and substance of the distribution agreement (the “**2024 Pharmaceutical Distribution Agreement**”) dated 15 November 2024 entered into between 深圳海王長健醫藥有限公司 (Shenzhen Neptunus Changjian Pharmaceutical Company Limited*) and 深圳海王藥業有限公司 (Shenzhen Neptunus Pharmaceutical Company Limited*) (a copy of the 2024 Pharmaceutical Distribution Agreement has been produced to the meeting and marked “C” and initialled by the chairman of the meeting for identification purpose) and all the transactions contemplated thereby be and are hereby approved, confirmed and ratified;
- (b) the proposed purchase caps under the 2024 Pharmaceutical Distribution Agreement for each of the three years ending 31 December 2025, 2026 and 2027 be and is hereby confirmed and approved; and
- (c) any one Director be and are hereby authorised to do all such acts and things, negotiate, approve, sign, initial, ratify and/or execute all documents which may in the opinion of the Director may consider necessary, appropriate, desirable or expedient to give effect to or in connection with the 2024 Pharmaceutical Distribution Agreement or any transactions contemplated thereunder and to agree to such variation, amendments or waiver or matters relating thereto (including any variation, amendments or waiver of such documents, which are not fundamentally different from those as provided under the 2024 Pharmaceutical Distribution Agreement) as are, in the opinion of the Director, in the interest of the Company and its shareholders as a whole.”

Please refer to the Company’s circular dated 10 December 2024 for details of the 2023 Supplemental Yidianyao Distribution Agreement, the 2024 Yidianyao Distribution Agreement and the 2024 Pharmaceutical Distribution Agreement.

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 10 December 2024

Registered Office:
Suite 1702
Neptunus Yinhe Technology Mansion
1 Keji Middle 3rd Road
Maling Community
Yuehai Sub-district
Nanshan District, Shenzhen
The PRC

Principal Place of Business in Hong Kong:
43/F
One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

* *For identification purpose only*

Notes:

- (1) A shareholder of the Company (the “**Shareholder**”) entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote instead of him. A proxy need not be a Shareholder. In the case of joint holders of shares of the Company (the “**Shares**”), any one of such joint holders may sign the form of proxy. However, if more than one of such joint holders are present at the EGM, whether personally or by proxy, that one of the joint Shareholders so present whose name stands first in the register of Shareholders in respect of such Shares shall alone be entitled to vote in respect thereof.
- (2) In order to be valid, the form of proxy together with a power of attorney or other authority (if any) under which it is signed or the notarised copy of such power of attorney or authority must be lodged, in the case of holders of H shares of the Company (the “**H Shares**”), with the Company’s H share registrar in Hong Kong, Tricor Investor Services Limited (the “**Company’s H Share Registrar**”), at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, and in the case of holders of domestic shares of the Company (the “**Domestic Shares**”), to the registered address of the Company at Suite 1702, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Maling Community, Yuehai Sub-district, Nanshan District, Shenzhen, The PRC no later than 24 hours before the time appointed for the holding of the EGM (i.e. not later than 10:00 a.m. on Monday, 30 December 2024) or any adjournment thereof (as the case may be).
- (3) The Shareholders or their proxies will be required to produce proof of their identities (and a copy of the form of proxy in case of proxies) when attending the EGM.
- (4) To ascertain the Shareholders’ entitlement to attend and vote at the Meeting, the register of Shareholders of the Company will be closed from Tuesday, 24 December 2024 to Tuesday, 31 December 2024, both days inclusive, during which period no transfer of Shares will be effected. As regards holders of H Shares, in order to qualify for attendance at the EGM, all transfers of H Shares accompanied by the relevant share certificates must be lodged with the Company’s H Share Registrar, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Monday, 23 December 2024.
- (5) The EGM is expected to last for no more than a day. The Shareholders or their proxies attending the EGM shall bear their own traveling, accommodation and meal expenses.
- (6) Voting at the EGM will be conducted by way of poll.
- (7) For any enquiries about this notice, please contact the contact person of general meetings, Mr. Huang Jian Bo, at +86 755 2640 1275.
- (8) References to time and dates in this notice are to Hong Kong time and dates.

As at the date of this notice, the executive Directors are Mr. Zhang Feng, Mr. Huang Jian Bo and Mr. Zhang Xiao Guang; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin and Mr. Jin Rui; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This notice, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this notice is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this notice misleading.

This notice will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company’s website at www.interlong.com.